You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Drug Price Trends for TAZVERIK


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for TAZVERIK

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
TAZVERIK 200MG TAB Epizyme, Inc. 72607-0100-00 240 15334.87 63.89529 EACH 2021-06-01 - 2026-05-31 FSS
TAZVERIK 200MG TAB Epizyme, Inc. 72607-0100-00 240 11948.21 49.78421 EACH 2022-01-01 - 2026-05-31 Big4
TAZVERIK 200MG TAB Epizyme, Inc. 72607-0100-00 240 15334.87 63.89529 EACH 2022-01-01 - 2026-05-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

TAZVERIK Market Analysis and Financial Projection

TAZVERIK: Market Analysis and Price Projections for the Groundbreaking EZH2 Inhibitor

TAZVERIK (tazemetostat) has emerged as a game-changing drug in the treatment of certain cancers, particularly epithelioid sarcoma and follicular lymphoma. As the first-in-class EZH2 inhibitor to gain FDA approval, TAZVERIK has garnered significant attention in the oncology community. This comprehensive analysis delves into the market dynamics, pricing strategies, and future projections for this innovative therapy.

The Rise of TAZVERIK in Cancer Treatment

TAZVERIK, developed by Epizyme, Inc., received its initial FDA accelerated approval in January 2020 for the treatment of epithelioid sarcoma. Just six months later, in June 2020, the drug secured additional approval for two follicular lymphoma indications. These rapid approvals underscore the drug's potential and the unmet medical need it addresses.

Mechanism of Action

As an EZH2 inhibitor, TAZVERIK works by targeting the epigenetic regulator EZH2, which plays a crucial role in cancer cell proliferation. By inhibiting this enzyme, TAZVERIK helps suppress tumor growth, offering a novel approach to cancer treatment.

Approved Indications

TAZVERIK is currently approved for:

  1. Adult and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
  2. Adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation and who have received at least two prior systemic therapies.
  3. Adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options.

Market Analysis: TAZVERIK's Growth Trajectory

The global EZH2 inhibitor market, led by TAZVERIK, is poised for substantial growth in the coming years.

Market Size and Projections

Global EZH2 inhibitor drug market will grow with a CAGR of more than 110% and is expected to surpass US$ 1 Billion by 2026.[1]

This remarkable growth rate is attributed to several factors:

  1. Extensive research and development in the EZH2 inhibitor sector
  2. High adoption rates of approved drugs
  3. Rising government initiatives
  4. Development of favorable reimbursement policies

Regional Market Dominance

The United States is expected to dominate the global EZH2 inhibitor drug market due to:

  1. High adoption rates
  2. Increasing research and development activities
  3. Rising prevalence of cancer

TAZVERIK's Market Performance

Since its launch, TAZVERIK has shown promising market performance:

  1. In 2020, TAZVERIK generated net product revenue of $11.4 million[3].
  2. The first quarter of 2022 saw TAZVERIK net product revenue reach $8.7 million, including $0.5 million related to third-party pharmaceutical company use in clinical trials[4].
  3. Commercial demand increased by 16% in Q1 2022 compared to Q4 2021[4].

Pricing Strategy and Market Positioning

Epizyme has adopted a strategic pricing approach for TAZVERIK, balancing the drug's value with market accessibility.

Current Pricing

As of 2022, the price for TAZVERIK is approximately $21,249 for a supply of 240 tablets (200 mg each)[8]. This translates to about $15,500 for a one-month supply[2].

Pricing Rationale

Epizyme's pricing strategy for TAZVERIK takes into account several factors:

  1. The ultra-rare status of epithelioid sarcoma
  2. Potential for market expansion to other cancer settings
  3. Positioning for use in larger markets

Comparative Pricing

TAZVERIK's price is relatively modest compared to some other orphan drugs:

The price of Tazverik is relatively modest compared with the $32,800 per month cost of Bayer's first-in-class Orphan drug Vitrakvi, which is indicated for the treatment of solid tumors with an NTRK gene fusion.[2]

This pricing strategy suggests that Epizyme is playing the long game, positioning TAZVERIK favorably for potential use in other cancer settings.

Market Expansion and Future Prospects

While TAZVERIK's initial approval for epithelioid sarcoma targets a small patient population, the drug's potential extends far beyond this rare cancer.

Follicular Lymphoma Market

The approval for follicular lymphoma significantly expands TAZVERIK's market potential:

  1. Follicular lymphoma accounts for 20-30% of all Non-Hodgkin lymphoma cases[2].
  2. The global Non-Hodgkin lymphoma market is projected to reach $10.8 billion by 2025[2].

Ongoing Clinical Trials

Epizyme is actively exploring TAZVERIK's potential in other indications:

  1. A Phase III study in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma is ongoing, with initial results expected in 2026[6].
  2. The company is planning to develop the drug for other solid tumors and hematological malignancies, both as monotherapy and in combination therapies[2].

Sales Projections

Industry analysts have provided optimistic sales projections for TAZVERIK:

  1. Consensus forecast sales of $103 million in 2021 (first full year on market)[2]
  2. Projected sales of $617 million by 2024[2]
  3. Tazverik Sales Opportunity > US$ 900 Million by 2026[1]

Competitive Landscape

As the first approved EZH2 inhibitor, TAZVERIK currently enjoys a unique position in the market. However, several competitors are in various stages of development:

  1. Constellation Pharmaceuticals' CPI-1205 and CPI-0209
  2. Pfizer's PF-06821497

These potential competitors are still in early development stages, with first regulatory approvals not expected until 2023[2]. This gives TAZVERIK a significant head start in establishing market presence.

Market Challenges and Opportunities

While TAZVERIK's market outlook is generally positive, there are both challenges and opportunities to consider.

Challenges

  1. Limited patient population for epithelioid sarcoma
  2. Potential competition from other EZH2 inhibitors in development
  3. Need for long-term efficacy and safety data

Opportunities

  1. Expansion into additional cancer indications
  2. Potential for combination therapies
  3. First-mover advantage in the EZH2 inhibitor market

Impact of Acquisition by Ipsen

In June 2022, French pharmaceutical company Ipsen announced its acquisition of Epizyme for $247 million[6]. This acquisition is expected to have significant implications for TAZVERIK's market presence and future development.

Potential Benefits of the Acquisition

  1. Increased resources for marketing and distribution
  2. Enhanced global reach
  3. Potential for accelerated clinical development in new indications

Ipsen's Strategy

Ipsen's CEO, David Loew, stated that the acquisition would allow the company to expand its oncology pipeline:

"Ipsen's capabilities and resources in oncology combined with Epizyme's will accelerate the growth of Tazverik to achieve its full potential in follicular lymphoma patients."[6]

This strategic move suggests a strong commitment to TAZVERIK's future development and market expansion.

Patient Access and Reimbursement

Ensuring patient access to TAZVERIK is crucial for its market success. Epizyme has implemented several initiatives to support patient access:

  1. Patient assistance program: Approximately 15% of total demand in Q1 2022 was supplied through this program[4].
  2. Engagement with payers to secure favorable reimbursement terms
  3. Education programs for healthcare providers to increase awareness of TAZVERIK's benefits

Future Market Trends and Projections

The EZH2 inhibitor market, led by TAZVERIK, is expected to see significant growth and evolution in the coming years.

Market Size Projections

  1. The global EZH2 inhibitor market is projected to surpass $1.2 billion by 2026[1].
  2. TAZVERIK alone is expected to achieve sales of over $900 million by 2026[1].

Emerging Trends

  1. Increased focus on combination therapies
  2. Exploration of EZH2 inhibitors in additional cancer types
  3. Growing interest in personalized medicine approaches using EZH2 inhibitors

Conclusion: TAZVERIK's Market Potential

TAZVERIK represents a significant advancement in cancer treatment as the first approved EZH2 inhibitor. Its unique mechanism of action, coupled with its expanding list of indications, positions it for substantial market growth. While challenges exist, including potential future competition and the need for long-term data, the overall outlook for TAZVERIK is highly promising.

The acquisition by Ipsen further strengthens TAZVERIK's market position, providing additional resources and global reach. As ongoing clinical trials explore new indications and combination therapies, TAZVERIK is poised to play an increasingly important role in the oncology treatment landscape.

With projected sales reaching into the hundreds of millions of dollars by 2026, TAZVERIK is set to become a major player in the cancer therapeutics market. Its success could pave the way for further development of epigenetic-targeted therapies, potentially revolutionizing cancer treatment approaches in the years to come.

Key Takeaways

  1. TAZVERIK is the first FDA-approved EZH2 inhibitor, with indications for epithelioid sarcoma and follicular lymphoma.
  2. The global EZH2 inhibitor market is projected to surpass $1 billion by 2026, with a CAGR of over 110%.
  3. TAZVERIK's current price is approximately $15,500 for a one-month supply, positioned strategically for potential expansion into larger markets.
  4. Ipsen's acquisition of Epizyme for $247 million is expected to accelerate TAZVERIK's growth and market penetration.
  5. Ongoing clinical trials are exploring TAZVERIK's potential in additional cancer indications and combination therapies.
  6. TAZVERIK sales are projected to reach over $900 million by 2026, indicating significant market potential.
  7. The drug's first-mover advantage in the EZH2 inhibitor market provides a strong foundation for future growth and development.

FAQs

  1. Q: What is TAZVERIK's mechanism of action? A: TAZVERIK is an EZH2 inhibitor that works by targeting the epigenetic regulator EZH2, which plays a crucial role in cancer cell proliferation. By inhibiting this enzyme, TAZVERIK helps suppress tumor growth.

  2. Q: How does TAZVERIK's pricing compare to other orphan drugs? A: TAZVERIK is priced at approximately $15,500 for a one-month supply, which is relatively modest compared to some other orphan drugs. For example, Bayer's Vitrakvi is priced at $32,800 per month.

  3. Q: What are the current approved indications for TAZVERIK? A: TAZVERIK is approved for epithelioid sarcoma in adults and pediatric patients aged 16 and older, and for two indications in follicular lymphoma in adult patients.

  4. Q: How might Ipsen's acquisition of Epizyme affect TAZVERIK's market presence? A: The acquisition is expected to provide increased resources for marketing and distribution, enhance global reach, and potentially accelerate clinical development in new indications.

  5. Q: What is the projected market size for EZH2 inhibitors by 2026? A: The global EZH2 inhibitor market is projected to surpass $1.2 billion by 2026, with TAZVERIK expected to achieve sales of over $900 million.

Sources cited: [1] https://www.prnewswire.com/news-releases/global-ezh2-inhibitor-market-report-2021-dosage-price--sales-analysis-of-tazverik-tazverik-sales-opportunity-of-900-million-forecast-to-2026-7-drugs-in-clinical-trial-301349536.html [2] https://clarivate.com/life-sciences-healthcare/blog/first-in-class-tazverik-launched-for-rare-sarcoma-wider-use-will-drive-market-value/ [3] https://www.globenewswire.com/news-release/2021/08/19/2283579/0/en/Global-EZH2-Inhibitor-Market-Opportunity-Sales-Clinical-Trials-Insight-2026.html [4] https://www.biospace.com/epizyme-reports-first-quarter-2022-financial-results-and-provides-business-update [6] https://www.biospace.com/ipsen-buying-epizyme-and-its-cancer-drug-tazverik [8] https://www.drugs.com/price-guide/tazverik

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.